| Scrip Code | 524742 |
|---|---|
| NSE Symbol | CAPLIPOINT |
| MSEI Symbol | NOTLISTED |
| ISIN | INE475E01026 |
| Name of company | CAPLIN POINT LABORATORIES LIMITED |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2026 |
| Date of end of financial year | 31-03-2027 |
| Date of board meeting when results were approved | 12-08-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 29-07-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | First quarter |
| Nature of report standalone or consolidated | Consolidated |
| Whether results are audited or unaudited for the quarter ended | Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | |
| Segment Reporting | Geographical |
| Description of single segment | |
| Start date and time of board meeting | 12-08-2026 10:45:00 |
| End date and time of board meeting | 12-08-2026 13:25:00 |
| Whether cash flow statement is applicable on company | |
| Type of cash flow statement | |
| Declaration of unmodified opinion or statement on impact of audit qualification | Not applicable |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-04-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-06-2026 | 30-06-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| 1 | Income | ||
| Revenue from operations | 61,036.00 | 61,036.00 | |
| Other income | 3,355.00 | 3,355.00 | |
| Total income | 64,391.00 | 64,391.00 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 10,706.00 | 10,706.00 |
| (b) | Purchases of stock-in-trade | 19,636.00 | 19,636.00 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | (5,822.00) | (5,822.00) |
| (d) | Employee benefit expense | 5,413.00 | 5,413.00 |
| (e) | Finance costs | 18.00 | 18.00 |
| (f) | Depreciation, depletion and amortisation expense | 2,162.00 | 2,162.00 |
| (f) | Other Expenses | ||
| 1 | Other Expenses | 9,755.00 | 9,755.00 |
| Total other expenses | 9,755.00 | 9,755.00 | |
| Total expenses | 41,868.00 | 41,868.00 | |
| 3 | Total profit before exceptional items and tax | 22,523.00 | 22,523.00 |
| 4 | Exceptional items | 0.00 | 0.00 |
| 5 | Total profit before tax | 22,523.00 | 22,523.00 |
| 6 | Tax expense | ||
| 7 | Current tax | 4,618.00 | 4,618.00 |
| 8 | Deferred tax | (5.00) | (5.00) |
| 9 | Total tax expenses | 4,613.00 | 4,613.00 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 17,910.00 | 17,910.00 |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | (1.00) | (1.00) |
| 16 | Total profit (loss) for period | 17,909.00 | 17,909.00 |
| 17 | Other comprehensive income net of taxes | (186.00) | (186.00) |
| 18 | Total Comprehensive Income for the period | 17,723.00 | 17,723.00 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | 17,691.00 | 17,691.00 | |
| Total profit or loss, attributable to non-controlling interests | 218.00 | 218.00 | |
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | 17,505.00 | 17,505.00 | |
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | 218.00 | 218.00 | |
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 1,520.00 | 1,520.00 | |
| Face value of equity share capital | 2 | 2 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 23.27 | 23.27 | |
| Diluted earnings (loss) per share from continuing operations | 23.21 | 23.21 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 23.27 | 23.27 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 23.21 | 23.21 | |
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | The above Unaudited Consolidated Financial Results for the quarter ended June 30, 2026, have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on August 12, 2026 and reviewed by the Statutory Auditors. 2) The Unaudited Consolidated Financial Results of the Company has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 (the Act) read with relevant rules issued thereunder (Ind AS) and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3) The Group is engaged in the sole activity of carrying on the business of Pharmaceutical Formulations and has identified two geographical segments as its reportable segments in accordance with Ind AS 108 – Operating Segments. Segment 1: Rest of the World. Segment 2: United States of America (USA). Accordingly, segment reporting has been presented along with the Consolidated results. 4)The Board of Directors at their meeting held on 14th May, 2026 declared an interim dividend of Rs. 4.00 (Rs. Four Only) per equity share (200 %) for the financial year 2025-26 and was paid to the shareholders on 8th June 2026. The Board of Directors at their meeting held today have recommended a final dividend of Rs. 4/- per equity share (200%) for the financial year 2025-26 which is subject to approval of the Shareholders in the ensuing Annual General Meeting of the Company. The total dividend for the financial year 2025-26 including the final dividend (subject to the approval of the Shareholders at the ensuing Annual General Meeting) will be Rs. 8/- per equity share (400%) of the face value of Rs. 2 each. 5) Previous periods' figures have been regrouped/reclassified to be in conformity with current period's classification/ disclosure, wherever necessary. |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-04-2026 | 01-04-2026 | |||||
| Date of end of reporting period | 30-06-2026 | 30-06-2026 | |||||
| Whether results are audited or unaudited | Unaudited | Unaudited | |||||
| Nature of report standalone or consolidated | Consolidated | Consolidated | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| 1 | Rest of the World | 47,607.00 | 47,607.00 | ||||
| 2 | USA | 13,429.00 | 13,429.00 | ||||
| 3 | Unallocated | 3,355.00 | 3,355.00 | ||||
| Total Segment Revenue | 64,391.00 | 64,391.00 | |||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | 64,391.00 | 64,391.00 | |||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| 1 | Rest of the World | 15,840.00 | 15,840.00 | ||||
| 2 | USA | 3,327.00 | 3,327.00 | ||||
| 3 | Unallocated | 3,355.00 | 3,355.00 | ||||
| Total Profit before tax | 22,522.00 | 22,522.00 | |||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | 22,522.00 | 22,522.00 | |||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| 1 | Rest of the World | 2,02,121.00 | 2,02,121.00 | ||||
| 2 | USA | 67,275.00 | 67,275.00 | ||||
| 3 | Unallocated | 1,50,239.00 | 1,50,239.00 | ||||
| Total Segment Asset | 4,19,635.00 | 4,19,635.00 | |||||
| Un-allocable Assets | 0.00 | 0.00 | |||||
| Net Segment Asset | 4,19,635.00 | 4,19,635.00 | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| 1 | Rest of the World | 35,080.00 | 35,080.00 | ||||
| 2 | USA | 6,979.00 | 6,979.00 | ||||
| 3 | Unallocated | 0.00 | 0.00 | ||||
| Total Segment Liabilities | 42,059.00 | 42,059.00 | |||||
| Un-allocable Liabilities | 0.00 | 0.00 | |||||
| Net Segment Liabilities | 42,059.00 | 42,059.00 | |||||
| Disclosure of notes on segments | |||||||
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-04-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-06-2026 | 30-06-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| Total Amount of items that will not be reclassified to profit and loss | |||
| 2 | Income tax relating to items that will not be reclassified to profit or loss | 0.00 | 0.00 |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| 1 | Exchange difference in translating the financial statements of foreign operations | (186.00) | (186.00) |
| Total Amount of items that will be reclassified to profit and loss | (186.00) | ||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 0.00 | 0.00 |
| 5 | Total Other comprehensive income | (186.00) | (186.00) |